£515.00

The 2023-2028 Outlook for Myasthenia Gravis in India

Subjects

Price data checked 3 days ago

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£515 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 88 days · 88 data points

Historical

Generating forecast…

Price Distribution

Price distribution over 88 days • 1 price levels

Days at Price

Price Analysis

Most common price: £515 (88 days, 100.0%)

Price range: £515 - £515

Price levels: 1 different prices over 88 days

Description

This study covers the latent demand outlook for myasthenia gravis across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for myasthenia gravis. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of myasthenia gravis as including all commonly understood services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Alexion Pharmaceutical, Avadel Pharmaceuticals, Baxter International, CSL Behring, F. Hoffmann-La Roche, Grifols,, Novartis, PLC. (Flamel Technologies), Shire, Takeda Pharmaceutical Company, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BGKZD5PH
Category: Books > Subjects
Domain: Amazon UK
Release Date: 14 September 2022
Listed Since: 29 September 2022

The 2023-2028 Outlook for Myasthenia Gravis in India

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2025-2030 World Outlook for Myasthenia Gravis

The 2025-2030 World Outlook for Myasthenia Gravis Treatments

The 2025-2030 World Outlook for Myasthenia Gravis Drugs

The 2025-2030 World Outlook for Myasthenia Gravis Drug Treatments

A Look into Myasthenia Gravis

Myasthenia Gravis, Part B: Volume 183 (International Review of Neurobiology, Volume 183)

Myasthenia Gravis, Part A: Volume 182 (International Review of Neurobiology, Volume 182)

Ocular Myasthenia Gravis (Experts' Perspectives on Medical Advances)

The 2023-2028 Outlook for Game Mouse and Keyboards in the United States

The 2023-2028 Outlook for In-Game Advertising for PC-Based Online Games in India

The 2023-2028 Outlook for Mobile Video Games in India

The 2023-2028 Outlook for Gaming Mouse and Keyboards in India

The 2023-2028 Outlook for Online Video Games in India

The 2023-2028 Outlook for Digital Games Software in India

The 2023-2028 Outlook for In-Game Advertising in India

The 2023-2028 Outlook for Gaming Mouse and Keyboards in the United States

The 2023-2028 Outlook for Video Games Software in India

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in India

The 2023-2028 Outlook for Motion Sickness Medications in India

The 2023-2028 Outlook for Motion Sickness Medications in the United States

The 2023-2028 Outlook for Game Engines and Development Software in India

The 2023-2028 Outlook for Social Video Games in India

The 2023-2028 Outlook for Video Games in India

The 2023-2028 Outlook for Social and Casual Video Games in India